<?xml version="1.0" encoding="UTF-8"?>
<p id="para3350">Diagnosis, treatment, and choice of optimal therapy for patients with HBV and HCV need to be improved in China. For HBV, nucleoside and nucleotide analogues such as lamivudine, adefovir, and telbivudine are not preferred by international guidelines but are still used in low-income areas,
 <xref rid="bib382" ref-type="bibr">382</xref>, 
 <xref rid="bib387" ref-type="bibr">387</xref> although the first-line antiviral drugs entecavir and tenofovir disoproxil fumarate are recommended by practice guidelines and are already on the reimbursement list.
 <xref rid="bib388" ref-type="bibr">
  <sup>388</sup>
 </xref> As tenofovir becomes cheaper and generic versions of tenofovir and entecavir are approved, appropriate therapies should be increasingly prescribed. Similarly, for patients with HCV, cheaper interferon-free direct-acting antiviral regimens that are included in reimbursement lists are urgently needed.
 <xref rid="bib389" ref-type="bibr">389</xref>, 
 <xref rid="bib390" ref-type="bibr">390</xref>
</p>
